Jan. 3, 2025 /Mpelembe Media/ —  Oncolytics Biotech Inc.’s progress in developing cutting-edge immunotherapies for cancer treatment is the article’s main subject. The piece highlights several key advancements, including clinical trial results and collaborations with other companies. Financial information regarding Oncolytics is included, along with a disclaimer about the nature of the publication.

Several innovative cancer therapies are in development, including immunotherapies and targeted treatments. Here are some of the key developments mentioned in the sources:

• Personalized mRNA cancer vaccines are being developed. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through this approach, highlighting its potential.
• Immunotherapies that “convert ‘cold’ tumors to ‘hot’ tumors” are under investigation. These therapies aim to make tumors more susceptible to the body’s immune response.
• Oncolytics Biotech is developing a variety of treatments, including:
  • Pelareorep, which continues to show promise for multiple cancer indications. Final efficacy results from the BRACELET-1 study in HR+/HER2- metastatic breast cancer demonstrated a median overall survival exceeding one year, and a two-year overall survival rate of nearly double that of patients on standard therapies.
  • A treatment for patients with advanced or metastatic pancreatic cancer, being evaluated in the GOBLIN trial.
• CARGO Therapeutics is developing a cell therapy, and expects to begin a phase 1 trial for non-Hodgkin’s lymphoma in Q1 2025.
• Immuneering Corporation is working on a therapy that combines a novel cancer drug with an existing cancer drug to restore additional data on MM-104 combined with nivolumab in first-line pancreatic cancer and on MM-104 in second-line pancreatic cancer.
• RenovoRx, Inc. is developing a novel drug-device combination therapy for locally advanced pancreatic cancer (LAPC) to deliver novel chemotherapies using a pressure-mediated delivery.
• Repare Therapeutics Inc. is working on a therapy for certain types of advanced cancers, with a focus on the treatment of tumours with specific DNA mutations.

These therapies represent a variety of approaches to cancer treatment, from personalized vaccines to cell-based immunotherapies and novel drug delivery systems, and are being developed by multiple companies. The sources suggest that these approaches aim to improve patient outcomes and offer treatment options for different types of cancer.

The sources mention several specific types of cancer that are being targeted by the therapies under development:

• Breast Cancer: The BRACELET-1 study focused on patients with HR+/HER2- metastatic breast cancer. This study is specifically mentioned in relation to Oncolytics Biotech’s Pelareorep therapy, which showed promising results including a median overall survival exceeding one year and a two-year overall survival rate nearly double that of standard therapies.
• Pancreatic Cancer: There are several mentions of therapies targeting pancreatic cancer.
  • Oncolytics Biotech is conducting the GOBLIN trial to evaluate a treatment for patients with advanced or metastatic pancreatic cancer.
  • Immuneering Corporation is working on a therapy for first-line and second-line pancreatic cancer, which involves combining a novel cancer drug (MM-104) with an existing cancer drug.
  • RenovoRx, Inc. is developing a novel drug-device combination therapy for locally advanced pancreatic cancer (LAPC).
• Non-Hodgkin’s Lymphoma: CARGO Therapeutics is developing a cell therapy and plans to begin a phase 1 trial for patients with Non-Hodgkin’s lymphoma.
• Advanced Cancers: Repare Therapeutics Inc. is working on a therapy for advanced cancers. The source mentions a focus on treating tumours with specific DNA mutations, but does not give a specific name for the types of cancers.

These cancers represent a range of solid tumours and blood cancers being targeted by innovative therapies, including immunotherapies, targeted treatments, and novel drug delivery systems. The sources particularly highlight the focus on breast and pancreatic cancers, indicating significant research and development efforts in these areas.

The article’s publication source is PR Newswire, and it appears on a business news website alongside other unrelated financial and technology news items. The overall tone is promotional, focusing on the positive aspects of Oncolytics’ research and development.